People · Operator
Named in public records as an officer, director or promoter · active 2010–2025 · Other, Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Telcare, Inc. | — | Other | Series B | $71.6M | $576.6M | 2010 |
| NeuroRx, Inc. | — | Pharmaceuticals | Series A | $6.7M | $140.7M | 2016 |
| NRX Pharmaceuticals, Inc. | — | Biotechnology | Seed | $3.5M | $12.3M | 2025 |
Jonathan Javitt at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jonathan Javitt on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Patrick Flynn | 2 | 8 |
| Chaim Hurvitz | 2 | 6 |
| Michael Taylor | 1 | 7 |
| Scott Carter | 1 | 6 |
| Michael Abrams | 1 | 6 |
| John Dwyer | 1 | 5 |
| James Lawrence | 1 | 2 |
| David Bjork | 1 | 2 |
| Casper C. De Clercq | 1 | 2 |
| Daniel Javitt | 1 | 1 |
| Jonathan C. Javitt | 1 | 1 |
| Scott C. Carter | 1 | 1 |
| Patrick C. Flynn | 1 | 1 |
| Kenneth C. Melani | 1 | 1 |
| John R. Dwyer, Jr. | 1 | 1 |
| Andrew Flanagan | 1 | 1 |
| Dennis McBride | 1 | 1 |
| Sherry Glied | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.